FMP

FMP

Enter

SEEL - Seelos Therapeutics,...

photo-url-https://images.financialmodelingprep.com/symbol/SEEL.png

Seelos Therapeutics, Inc.

SEEL

NASDAQ

Inactive Equity

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was incorporated in 1987 and is headquartered in New York, New York.

0.37 USD

0 (0%)

SEEL Financial Statements

Year

2023

2022

2021

2020

Total Revenue

2.2M

0

0

0

Cost of Revenue

30.12M

53k

0

0

Gross Profit

-27.91M

-53k

0

0

Operating Expenses

12.59M

70.92M

61.67M

18.76M

Research and Development

30.12M

58.62M

46.65M

10.98M

Selling, General & Administrative Expenses

12.53M

12.3M

15.02M

7.78M

Selling & Marketing Expenses

-57k

0

0

0

General & Administrative Expenses

12.59M

12.3M

15.02M

7.78M

Other Expenses

0

-3.02M

230k

0

Operating Income

-40.5M

-70.92M

-61.67M

-18.76M

Total Other Income/Expenses Net

2.62M

-2.62M

-4.38M

-342k

Income Before Tax

-37.88M

-73.53M

-66.05M

-19.1M

Income Tax

0

2.6M

1.49M

119k

Net Income

-37.88M

-76.14M

-67.53M

-19.22M

Basic EPS

-7.73

-21.48

-22.29

-12.88

EPS Diluted

-7.73

-21.48

-22.29

-12.88

Basic Average Shares

4.9M

3.54M

3.03M

1.49M

Diluted Average Shares

4.9M

3.54M

3.03M

1.49M

EBITDA

-37.75M

-73.47M

0

0

Retained Earning Schedule

Year

2023

2022

2021

2020

Retained Earnings (Previous Year)

-214.74M

-141.21M

-75.16M

-56.06M

Net Income

-37.88M

-76.14M

-67.53M

-19.22M

Stock Repurchases

-1.2M

0

0

0

Dividend Paid

0

0

0

0

Retained Earnings

-252.63M

-214.74M

-141.21M

-75.16M

Other Distributions

-39.08M

-73.53M

-66.05M

-19.1M

PPE Schedule

Year

2023

2022

2021

2020

Gross PPE

15k

72k

39k

0

Annual Depreciation

57k

53k

61.67M

18.76M

Capital Expenditure

0

0

0

0

Net PPE

-42k

19k

-61.63M

-18.76M

Intangible and Goodwill Schedule

Year

2023

2022

2021

2020

Acquisitions and Adjustments

0

0

0

0

Goodwill (Previous Year)

0

0

0

0

Goodwill

0

0

0

0

All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep